Literature DB >> 21984138

Prognosis of surgically resected lung cancer with extremely high preoperative serum carcinoembryonic antigen level.

Nobumasa Takahashi1, Kenji Suzuki, Kazuya Takamochi, Shiaki Oh.   

Abstract

PURPOSE: The aim of this study was to investigate the prognosis of resected lung cancer patients with extremely high carcinoembryonic antigen (CEA) levels. Several reports have indicated that increased preoperative serum CEA levels are associated with a dismal outcome after surgery, whereas others have reported long-term survival among patients with extremely high preoperative CEA levels. We investigated whether preoperative serum CEA levels, especially extremely high levels, were related to the prognosis of non-small-cell lung cancer (NSCLC) after surgery.
METHODS: From September 1996 to January 2008, a total of 649 patients underwent surgical treatment for NSCLC at Juntendo University Hospital. We conducted a retrospective review to investigate the prognostic significance of the preoperative CEA level in these patients. We also investigated the prognosis of patients with an extremely high preoperative CEA level (>30 ng/ml).
RESULTS: The 5-year survival rates were 78.4% and 63.0% for patients with normal and abnormal preoperative CEA levels, respectively. The survival rate was significantly worse for patients with abnormal preoperative CEA levels (P = 0.0002). In all, 28 patients had preoperative CEA levels >30 ng/ml. Although most of these patients showed a poor prognosis, 7 (25.0%) were longterm survivors (>4 years).
CONCLUSION: An abnormal preoperative CEA level suggests a poor prognosis for patients with NSCLC after surgery. Nevertheless, a few patients with an extremely high preoperative CEA level had long-term survival. Even if the preoperative CEA is extremely high, we perform a careful survey for distant or intrathoracic metastases and should not overlook operable cases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21984138     DOI: 10.1007/s11748-011-0797-x

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  13 in total

1.  Preoperative serum carcinoembryonic antigen level is a prognostic factor in women with early non-small-cell lung cancer.

Authors:  Wen-Hu Hsu; Chien-Sheng Huang; Han-Shui Hsu; Wen-Jen Huang; Hui-Chen Lee; Biing-Shiun Huang; Min-Hsiung Huang
Journal:  Ann Thorac Surg       Date:  2007-02       Impact factor: 4.330

2.  Clinical predictors of N2 disease in non-small cell lung cancer.

Authors:  K Takamochi; K Nagai; K Suzuki; J Yoshida; Y Ohde; Y Nishiwaki
Journal:  Chest       Date:  2000-06       Impact factor: 9.410

3.  Measurement of carcinoembryonic antigen in patients with bronchogenic carcinoma.

Authors:  P B Dent; P B McCulloch; O Wesley-James; R MacLaren; W Muirhead; C W Dunnett
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

4.  Carcinoembryonic antigen in 228 patients with carcinoma of the lung.

Authors:  R G Vincent; T M Chu; T B Fergen; M Ostrander
Journal:  Cancer       Date:  1975-12       Impact factor: 6.860

5.  Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer.

Authors:  K Suzuki; K Nagai; J Yoshida; M Nishimura; K Takahashi; Y Nishiwaki
Journal:  J Thorac Cardiovasc Surg       Date:  1999-03       Impact factor: 5.209

6.  Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease.

Authors:  Morihito Okada; Wataru Nishio; Toshihiko Sakamoto; Kazuya Uchino; Tsuyoshi Yuki; Akio Nakagawa; Noriaki Tsubota
Journal:  Ann Thorac Surg       Date:  2004-07       Impact factor: 4.330

7.  Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer.

Authors:  Noriyoshi Sawabata; Mitsunori Ohta; Shin-ichi Takeda; Hirotsugu Hirano; Yoshitomo Okumura; Hiroki Asada; Hajime Maeda
Journal:  Ann Thorac Surg       Date:  2002-07       Impact factor: 4.330

8.  The prognostic value of carcinoembryonic antigen in T1N1M0 and T2N1M0 non-small cell carcinoma of the lung.

Authors:  Ryuta Fukai; Yukinori Sakao; Motoki Sakuraba; Shiaki Oh; Kazu Shiomi; Satoshi Sonobe; Yuichi Saitoh; Hideaki Miyamoto
Journal:  Eur J Cardiothorac Surg       Date:  2007-07-23       Impact factor: 4.191

9.  Prognostic value of preoperative carcinoembryonic antigen (CEA) plasma levels in patients with bronchogenic carcinoma.

Authors:  J P Concannon; M H Dalbow; S E Hodgson; J J Headings; E Markopoulos; J Mitchell; W J Cushing; G A Liebler
Journal:  Cancer       Date:  1978-09       Impact factor: 6.860

10.  Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma.

Authors:  Yukinori Sakao; Shinji Tomimitsu; Yuji Takeda; Masafumi Natsuaki; Tsuyoshi Itoh
Journal:  Eur J Cardiothorac Surg       Date:  2004-04       Impact factor: 4.191

View more
  4 in total

Review 1.  Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Authors:  Philip A J Crosbie; Rajesh Shah; Yvonne Summers; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2013-10

2.  Positron-emission tomography CT to identify local recurrence in stage I lung cancer patients 1 year after stereotactic body radiation therapy.

Authors:  M Essler; J Wantke; B Mayer; K Scheidhauer; R A Bundschuh; B Haller; S T Astner; M Molls; N Andratschke
Journal:  Strahlenther Onkol       Date:  2013-04-24       Impact factor: 3.621

3.  The prognostic value of carcinoembryonic antigen levels in blood and intraoperative pleural lavage fluid in non-small-cell lung cancer.

Authors:  Tevfik Ilker Akcam; Ufuk Cagirici; Ayse Gul Ergonul; Ali Ozdil; Onder Kavurmaci; Kutsal Turhan; Alpaslan Cakan; Burcu Barutcuoglu
Journal:  Kardiochir Torakochirurgia Pol       Date:  2017-06-30

4.  Combined neat model for the prognosis of postoperative stage III-N2 non-small cell lung cancer.

Authors:  Yirui Zhai; Zhouguang Hui; Yu Men; Yang Luo; Yushun Gao; Jingjing Kang; Xin Sun; Jianyang Wang
Journal:  Thorac Cancer       Date:  2020-07-29       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.